PRE MARKET: LTIM.NS (LTIMindtree) NSE Feb 2026 $100.00m deal: model +28.09%
The LTIM.NS stock opens pre-market after news that LTIMindtree won a $100.00m contract with a European medtech firm, a deal that supports near-term revenue visibility. At INR 4,959.50 the share trades below its 50-day average of INR 5,878.82, leaving valuation and momentum questions for investors. We examine fundamentals, technicals, and model forecasts to show how the medtech order and current metrics shape the LTIM.NS stock outlook for Indian market traders and global clients.
LTIM.NS stock market snapshot and news impact
LTIM.NS stock trades pre-market on the NSE at INR 4,959.50 with volume 203,502.00 and a one-day change of +1.43%. The company reported a new $100.00m medtech deal, reported by Reuters, that should add near-term revenue and order book visibility Reuters.
The contract is the most important near-term catalyst and supports LTIMindtree’s vertical exposure to healthcare technology. We view the deal as demand proof in a higher-margin digital segment and a reason for active traders to reweight positions ahead of earnings season.
LTIM.NS stock fundamentals and valuation
LTIMindtree shows solid per-share metrics: EPS 160.38, PE 30.13, and book value per share 802.19. Market cap stands at 1,432,059,436,091.00 INR and the company carries low leverage with debt to equity 0.18.
Valuation multiples sit above sector averages: price to sales 3.51 and price to book 6.04, reflecting premium for digital capabilities. Investors should weigh premium multiples against revenue growth of 7.01% (FY), strong ROE 20.57%, and a dividend per share of 67.00 INR.
LTIM.NS stock technicals and trading signals
Technicals show short-term weakness: RSI 21.28 (oversold) and MACD histogram negative at -66.34. Price is below the 50-day average INR 5,878.82 and 200-day average INR 5,529.64, suggesting the trend remains down on momentum.
Volatility indicators are elevated with ATR 172.38 and Bollinger lower band at INR 4,680.05, which frames support near the band. Traders should watch daily volume and RSI for mean-reversion signals or a breakout on renewed client wins.
LTIM.NS stock financial health and growth drivers
Cash per share is 474.79 INR and free cash flow per share is 137.87 INR, giving LTIMindtree strong liquidity and funding for investments. Operating margins are healthy at roughly 15.05% and net margin 11.66%, driven by digital services demand.
Growth levers include healthcare digital, cloud partnerships with AWS, and platform deals. Risks to growth include tougher pricing in legacy services and slower-than-expected deal conversion in North America and Europe.
Meyka AI stock grade and LTIM.NS stock forecast
Meyka AI rates LTIM.NS with a score out of 100: Meyka AI rates LTIM.NS with a score of 79.45 / 100, Grade B+, Suggestion BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a yearly price of INR 6,352.24 and a monthly projection of INR 4,334.78. Compared with the current price INR 4,959.50, the yearly forecast implies an upside of +28.09% while the monthly projection implies a near-term downside of -12.60%. Forecasts are model-based projections and not guarantees.
Trading strategy for LTIM.NS stock in pre-market
For short-term traders, use layered entries near technical support at INR 4,680.05 and tighten stops below the lower Bollinger band. For swing or buy-and-hold investors, weigh the Meyka forecast upside of 28.09% against a premium valuation and current momentum.
Position size should reflect volatility; average volume 317,911.00 suggests moderate liquidity but watch for spikes around earnings on 22 Apr 2026. Use earnings and deal flow as re-evaluation points.
Final Thoughts
Key takeaways for LTIM.NS stock on 24 Feb 2026: the Reuters-reported $100.00m medtech deal materially improves revenue visibility and is the primary near-term catalyst. Fundamentals remain solid with EPS 160.38, PE 30.13, strong ROE 20.57%, and healthy cash per share 474.79 INR. Technicals show momentum weakness and oversold conditions, so traders should expect short-term volatility. Meyka AI’s forecast model projects a yearly target of INR 6,352.24, implying a +28.09% upside from the current INR 4,959.50; the model also shows a near-term monthly projection of INR 4,334.78, a -12.60% move. Use deal updates and the April 2026 earnings date as decision points. Meyka AI-powered market analysis highlights the trade-off between premium valuation and concrete growth wins; manage risk with clear stops and size allocations.
FAQs
What drives the recent move in LTIM.NS stock?
The immediate driver is a Reuters-reported $100.00m medtech contract. The deal improves revenue visibility and supports higher-margin digital services. Investors should monitor deal conversions and the April 2026 earnings date for confirmation.
What is Meyka AI’s short and long forecast for LTIM.NS stock?
Meyka AI’s model projects a monthly price of INR 4,334.78 and a yearly price of INR 6,352.24. That implies a near-term downside of -12.60% and a yearly upside of +28.09%, model-based and not guaranteed.
Is LTIM.NS stock fairly valued by common metrics?
LTIMindtree trades at PE 30.13 and PB 6.04, above sector averages, reflecting growth expectations. Strong margins and ROE offset the premium, but valuation remains a key risk for investors.
How should traders manage risk in LTIM.NS stock pre-market?
Use layered entries near technical support and set tight stops below the lower Bollinger band at INR 4,680.05. Keep position sizes aligned with volatility and reassess around earnings and deal announcements.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.